GSK's chronic hepatitis B drug helps one in five achieve functional cure in key studies

GSK said its ‌experimental chronic hepatitis B drug helped nearly one in five patients achieve a functional cure in late-stage studies, raising hopes for a finite treatment course as an alternative to lifelong antiviral ​pills.